Assault on resistance: The use of computational chemistry in the development of anti-HIV drugs

Current Pharmaceutical Design

Volumn 12, Issue 15, 2006, Pages 1843-1856

  Kroeger Smith, Marilyn B ^a,b   Smith Jr , Richard H ^a,b   Jorgensen, William L ^a,b  

^a MCDANIEL COLLEGE   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

Computational chemistry; Free energy perturbation (FEP); HIV reverse transcriptase; HIV protease; Non nucleoside (NNRTI) inhibitors

Indexed keywords

9 CHLORO 4,5,6,7 TETRAHYDRO 5 METHYL 6 (3 METHYL 2 BUTENYL)IMIDAZO[4,5,1 JK][1,4]BENZODIAZEPINE 2(1H) THIONE; AMPRENAVIR; ANTIRETROVIRUS AGENT; CAPRAVIRINE; DELAVIRDINE; EFAVIRENZ; EMIVIRINE; ENFUVIRTIDE; ETRAVIRINE; INDINAVIR; KYNOSTATIN 272; LOPINAVIR; MOZENAVIR; MVT 101; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TIPRANAVIR; TIVIRAPINE; TROVIRDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BINDING AFFINITY; DRUG APPROVAL; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME MECHANISM; HIGH THROUGHPUT SCREENING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR DYNAMICS; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; DRUG DESIGN; HIV INFECTIONS; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MODELS, CHEMICAL; MOLECULAR STRUCTURE; PROTEIN BINDING; REVERSE TRANSCRIPTASE INHIBITORS; THERMODYNAMICS;

EID: 33646503271     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776873581     Document Type: Review

References (95)

1. Condra, JH, Miller, MD, Hazuda, DJ, Emini, EA. Potential new therapies for the treatment of HIV-1 infection. Annu. Rev. Med. 2002; 53, 541-555.
2. Vacca JP, Conda JH. Clinically effective HIV-1 protease inhibitors. Drug Discov Today 1997; 2: 261-272.
3. Hertogs K, Bloor S, Kemp SD, Van den Eynde C, Alcorn TM, Pauwels R, Van Houtte M, Staszewski S, Miller V, Larder BA. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: A survey of over 6000 samples. AIDS 2002; 14: 1203-1210.
4. Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, Grant RM. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy. AIDS 1999; 13: F35-F43.
5. Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, Albert J, Schipper P, Gulnik S, Boucher CA. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 1999; 13: 2349-2359.
6. Walmsley S, Berstein, B, King M, Arribas J, Beall G, Ruane P, Johnson M, Johnson D, Japour A, Brun S, Sun E. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346: 2039-2046.
7. Miller M, Schneider J, Sathyanarayana B, Toth MV, Marshall GR, Clawson L, Selk L, Kent SBH, Wlodawer A. Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 angstrom resolution. Science 1989; 246: 1149-1152.
8. Gustchina A, Sansom C, Prevost M, Richelle J, Wodak SY, Wlodawer A, Weber IT. Protein Eng 1994; 7: 309-317.
9. Velazquez CA, Luque, FE. The application of thermodynamic methods in drug design. Thermochimica Acta, 2001; 380: 217-227.
10. DesJarlais R, Seibel GL, Kuntz ID. Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus-1 protease. Proc Natl Acad Sci USA 1990; 87: 6644-48.
11. Surles M, Richardson JS, Richardson DC, Brooks F, Jr. Sculpting proteins interactively: continual energy minimization embedded in a graphical modeling system. Protein Sci 1994; 3: 198-210.
12. Holloway MK, Wai JM, Halgren TA, Fitzgerald PMD, Vacca JP, Dorsey BD, Levin RB, Thompson WJ, Chen LJ, deSolms SJ, Gaffin N, Ghosh AK, Giuliani EA, Graham SL, Guare JP, Hungate RW, Lyle TA, Sanders WM, Tucker UJ, Wiggins M, Wiscount CM, Woltersdorf OW, Young SD, Darke PL, Zugay JA. A Priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site. J Med Chem 1995; 38: 305-317.
13. Weber I, Harrison RW. Molecular mechanics calculations on HIV-1 protease with peptide substrates correlate with experimental data. Protein Eng 1996; 9: 679-690.
14. Hansson T, Marelius J, Aquist J. Ligand binding affinity prediction by linear interaction energy methods. J Comput-Aided Mol Design 1998; 12: 27-35.
15. Jaskolski M, Tomasselli AG, Sawyer TK, Staples DG, Heinrickson RL, Schneider J, Kent SBH, Wlodawer A. Structure at 2.5 Ang resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with an hydroxyethylene-based inhibitor. Biochemistry 1991; 30: 1600-1609.
16. Lee H, Darden TA, Pedersen LG. An ab initio quantum mechanical model for the catalytic mechanism of HIV-1 protease. J Am Chem Soc 1996; 118: 3946-3950.
17. Venturini A, Lopez-Ortiz F, Alvarez, JM, Gonzalez J. Theoretical proposal of a catalytic mechanism for the HIV-1 protease involving an enzyme-bound tetrahedral intermediate. J Am Chem Soc 1998; 120: 1110-1111.
18. Hyland LJ, Tomaszek TA, Jr, Roberts GD, Carr SA, Magaard VW, Bryan HL, Fakhoury SA, Moore ML, Minnich MD, Culp JS, Desjarlias RL, Meek TD. Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent isotope effects to elucidate details of chemical mechanism. Biochemistry 1991; 30: 8441-8453.
19. Ala PJ, Huston EE, Klabe RM, McCabe DD, Duke JL, Rizzo CJ, Korant BD, DeLoskey RJ, Lam PYS, Hodge CN, Chang C-H. Molecular basis of HIV-1 protease drug resistance: Structural analysis of mutant proteases complexed with cyclic urea inhibitors. Biochemistry 1997; 36: 1573-1580.
20. Wallqvist A, Smythers G, Covell G. A cooperative folding unit in HIV-1 protease. Implications for protein stability and occurrence of drug-induced mutations. Prot Eng 1998; 11: 999-1005.
21. Chen Z, Li Y, Chen E, Hall DL, Darke PL, Culbeson C, Shafer JA, Kuo LC. Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of HIV protease. J Biol Chem 1994; 269: 26344-26348.
22. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DG, Quintero J, Rhodes A, Robbins HL, Roth E, Shivaprakash M, Titus D, Yang T, Tepplert H, Squires KE, Deutsch PJ, Emini EA. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374: 569-571.
23. Schaffer L, Verkhivker GM. Predicting Structural Effects in HIV-1 protease mutant complexes with flexible ligand docking and protein side-chain optimization. Proteins Struct Funct Genet 1998; 33: 295-310.
24. Dominy BN, Brooks C, III. Methodology for protein-ligand binding studies: application to a model for drug resistance, the HIV/FIV protease system. Proteins Struct Funct Genet 1999; 36; 318-331.
25. Weber I, Harrison RW. Molecular mechanics analysis of drug-resistant mutants of HIV protease. Protein Eng 1999; 12: 469-474.
26. Shenderovich MD, Tseitin V, Fisher, CL, Ramnarayan K. Molecular modeling and binding energy calculations for drug resistant mutations in HIV-1 protease-inhibitor complexes. Peptides: The Wave of the Future, Proceedings of the Second International and the Seventeenth American Peptide Symposium, San Diego, CA, United States, 2001, 418-419. Editors: Lebl, Michal; Houghten, Richard A.
27. Wang W, Kollman PA. Computational study of protein specificity: The molecular basis of HIV-1 protease drug resistance. Proc Natl Acad Sci USA 2001; 98: 14937-14942.
28. Nair AC, Miertus S, Tossi A, Romeo D. Computational studies of the resistance patterns of mutant HIV-1 aspartic proteases towards ABT-538 (ritonavir) and the design of new derivatives. J Mol. Graphics Modell 2002; 21: 171-179.
29. Beveridge DL, DiCapua FM. Free energy via molecular simulation: Applications to chemical and biomolecular systems. Annu Rev Biophys Chem 1989; 18: 431-492.
30. Ferguson DM, Radmer RJ, Kollman PA. Detemination of the relative binding free energies of peptide inhibitors to the HIV-1 protease. J Med Chem 1991; 34: 2654-2659.
31. Rick SW, Topol IA, Erickson JW, Burt, SK. Molecular mechanisms of resistance: Free energy calculations of mutation effects on inhibitor binding to HIV-1 protease. Prot Sci 1998; 7: 1750-1756.
32. Rosin CD, Belew RK, Morris GM, Olson AJ, Goodsell DS. Coevolutionary analysis of resistance-evading peptidomimetic inhibitors of HIV-1 protease. Proc Natl Acad Sci USA 1999; 96: 1369-1374.
33. Rosin D, Belew RK, Walker WL, Morris GM, Olson AJ, Goodsell DS. Coevolution and subsite decomposition for the design of resistance-evading HIV-1 protease inhibitors. J Mol Biol 1999; 287: 77-92.
34. Stoffler D, Sanner, MF, Morris GM, Olson AJ, Goodsell DS. Evolutionary analysis of HIV-1 protease inhibitors: Methods for design of inhibitors that evade resistance. Proteins Struct Funct Des 2002; 48: 63-74.
35. Mitchell, M. An Introduction to Genetic Algorithms, 1996, MIT press, Cambridge, MA.
36. Markowitz M, Mo H, Kempf DJ, Norbeck DW, Bhat TN, Erickson JW, Ho DD. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol 1995; 69: 701-706.
37. Gong Y-F, Robinson BS, Rose RE, Deminie C, Spicer TP, Stock D, Colonno RJ, Lin P-F. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob Agents Chemother 2000; 44: 2319-2326.
38. Hertogs K, de Bethune M-P, Miller V, Ivens T, Schel P, Van Cauwenberge A, Van den Eynde C, van Gerwen V, Azijn H, van Houtte M, Peeters F, Staszewske S, Conat M, Bloor S, Kemp S, Larder B, Pauwels R. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998; 42: 269-276.
39. Shenderovich MD, Kagan M, Heseltine PNR, Ramnarayan K. Structure-based phenotyping predicts HIV-1 protease inhibitor resistance. Protein Sci 2003; 12: 1706-1718.
40. Fairlie P, Tyndall JDA, Reid RC, Wong AK, Abbenante G, Scanlon MJ, March DR, Bergman DA, Chai CLL, Burkett BA. Conformational selection of inhibitors and substrates by proteolytic enzymes: Implications for drug design and polypeptide processing. J Med Chem 2000; 43: 1271-1281.
41. Markland W, Rao BG, Parson JD, Black J, Zuchowski L, Tisdale M, Tung R. Structural and kinetic analysis of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir. J Virol 2000; 74: 7636-7641.
42. Chen YZ, Gu XL, Cao ZW. Can an optimization/scoring procedure in ligand-protein docking be employed to probe drug-resistant mutations in proteins? J Molec Graphics Modell 2001; 19; 560-570.
43. Wang J, Kollmann PA, Kunz ID. Flexible ligand-docking: A multistep approach. Proteins 1999; 36: 1-19.
44. Frecer V, Miertus S. Interactions of ligands with macromolecules: Rational design of specific inhibitors of aspartic protease of HIV-1. Macromolecular Chem Phys 2002; 203: 1650-1657.
45. Hensen C, Hermann JC, Nam K, Ma S, Gao J, Holtje H-D. A combined QM/Mm approach to protein-ligand interactions: Polarization effects of the HIV-1 protease on selected high affinity inhibitors. J Med Chem 2004; 47: 6673-6680.
46. Smith RH Jr, Michejda J, Hughes SH, Arnold E, Janssen PAJ, Smith MBK. Structure and Mechanism of action of nonnucleoside inhibitors of HIV-1 reverse transcriptase: strategies to combat drug resistance. J Mol Struct (Theo Chem) 1998; 423: 67-77.
47. Kohlstaedt LA, Wang J, Friedman, JM, Rice A, Steitz TA. Crystal structure at 3.5A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992; 256: 1783-1790.
48. Ding J, Das K, Tantillo C, Zhang W, Clark AD, Jr, Jessen S, Lu X, Hsiou Y, Jacobo-Molina A, Andries K, Pauwels R, Moereels H, Koymans L, Janssen PAJ, Smith RH Jr, Smith MBK, Michejda CJ, Hughes SH, Arnold E. Structure of HIV-1 reverse transcriptase in a complex with the nonnucleoside inhibitor α-APA 95845 at 2.8A resolution. Structure 1995; 3: 365-379.
49. Smith MBK, Rouzer C, Taneyhill LA, Smith NA, Hughes SH, Boyer PL, Janssen PAJ, Moereels H, Koymans L, Arnold E, Ding J, Das K, Zhang W, Michejda CJ, Smith RH, Jr. Molecular Modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: Total energy of complexation as a predictor of drug placement and activity. Protein Sci 1995; 4: 2003-2222.
50. Dewar MJS, Thiel W. Ground States of Molecules. 38. The MNDO method. Approximations and parameters. J Am Chem Soc 1977; 99: 4899-4907.
51. Schafer W, Friebe WG, Leinert H, Metens A, Poll T, Von der Saal, W, Zilch H, Nuber B, Ziegler, M. nonnucleoside inhibitors of reverse transcriptase: Molecular modeling and x-ray structure investigations. J Med Chem 1993; 36: 726-732.
52. Gussio R, Pattabiraman N, Zaharevitz DW, Kellogg GE, Topol IA, Rice J, Schaeffer CA, Erickson JW, Burt SK. All-atom models for the nonnucleoside binding site of HIV-1 reverse transcriptase complexed with inhibitors: A 3D QSAR approach. J Med Chem 1996; 39: 1645-1650.
53. Smerdon SJ, Jager J, Wang J, Kohlstaedt LA, Chirino AJ, Friedman JM, Rice PA, Steitz TA. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1994; 91: 3911-3915.
54. Smith MBK, Michejda CJ, Hughes SH, Boyer PL, Janssen PAJ, Andries K, Buckheit R W Jr, Smith RH, Jr. Molecular modeling of HIV-1 reverse transcriptase drug-resistant mutant strains: Implications for the mechanism of polymerase action. Protein Eng 1997; 10: 1379-1383.
55. Rao GS, Kataria S, Siddiqui MI. A peptide inhibitor of HIV-1 reverse transcriptase using α,β-dehydro residues: A structure-based computer model. J Biomolec Struct Dynamics 1998; 16: 347-354.
56. Sarafinanos SG, Kortz U, Pope MT, Modak MJ. Mechanism of polyoxometalate-mediated inactivation of DNA polymerases: an analysis with HIV-1 reverse transcriptase indicates specificity for the DNA-binding cleft. Biochem J 1996; 319: 619-626.
57. Das K, Ding J, Hsiou Y, Clark AD, Jr, Moereels H, Koyman, L, Andires K, Pauwels R, Janssen PAJ, Boyer PL, Clark P, Smith RH, Jr, Smith MBK, Michejda CJ, Hughes, SH, Arnold E. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. J Molec Biol 1996; 264: 1085-1100.
58. Pitera J, Kollman P. Designing an optimum guest for a host using multimolecule free energy calculations: Predicting the best ligand for Rebek's "Tennis Ball". J Amer Chem Soc 1998; 120: 7557-7567.
59. Gilson MK, Honig B. Calculation of the total electrostatic energy of a macromolecular system: Solvation energies, binding energies and conformational analysis. Proteins Struct Funct Genet 1988; 4: 7-18.
60. Sharp KA, Honig B. Electrostatic interactions in macromolecules: Theory and applications. Annu Rev Biophys Chem 1990; 19: 301-332.
61. Radmer J, Kollman P. The application of three approximative free energy calculation methods to structure based ligand design: Trypsin and its complex inhibitors. J Comput Aided Drug Des 1998; 12: 215-227.
62. Smith MBK, Lamb ML, Tirado-Rives, Jorgensen WL, Michejda CJ, Ruby SK, Smith RH Jr. Monte Carlo calculations on HIV-1 reverse transcriptase complexed with the nonnucleoside inhibitor 8-Cl TIBO: Contribution of the L100I and Y181C variants to protein stability and biological activity. Protein Eng 2000; 13: 413-421.
63. Straatsma TP. Free Energy by Molecular Simulation. Rev Comp Chem 1996; 9: 81-127.
64. Jones-Hertoz D, Jorgensen WL. Binding affinities for sulfoamide inhibitors with human thrombin using Monte Carlo siumulations with a linear response method. J Med Chem 1997; 40: 1539-1549.
65. Rizzo R, Wang D-P, Tirado-Rives J, Jorgensen WJ. Validation of a model for the complex of HIV-1 reverse transcriptase with sustiva through computation of resistance profiles. J Amer Chem Soc 2000; 122: 12898-12900.
66. Wang D-P, Rizzo RC, Tirado-Rives J, Jorgensen WL. Antiviral drug design: Computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs. Bioorg Med Chem Lett 2001; 11: 2799-2802.
67. Udier-Blagovic M, Watkins K, Tirado-Rives J, Jorgensen WL. Activity predictions for efavirenz analogues with the K103N mutant of HIV reverse transcriptase. Bioorg Med Chem Lett 2003; 13: 3337-3340.
68. Udier-Blagovic M, Tirado-Rives J, Jorgensen WL. Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125. J Amer Chem Soc 2003; 125: 6016-6017.
69. Rizzo RC, Tirado-Rives J, Jorgensen WL. Estimation of binding affinities for HEPT and nevirapine analogs with HIV-1 reverse transcriptase via Monte Carlo calculations. J Med Chem 2001; 44: 145-154.
70. Rizzo RC, Blagovic MU, Wang D-P, Watkins EK, Smith, MBK, Smith RH, Jr, Tirado-Rives J, Jorgensen WL. Prediction of activity for nonnucleoside inhibitors with HIV reverse transcriptase based on Monte Carlo simulations. J Med Chem 2002; 45; 2970-2987.
71. Smith MBK, Ruby S, Horouzhenko S, Buckingham B, Richarson J, Puleri I, Potts E, Jorgensen WL, Arnold E, Zhang W, Hughes SH, Michejda, CJ, Smith RH, Jr. HIV-1 reverse transcriptase variants: Molecular modeling of Y181C, V106A, L100I, and K103N mutations with nonnucleoside inhibitors using Monte Carlo simulations in combination with a linear response method. Drug Discov Design 2004; 18: 151-163.
72. Mao C, Sudbeck EA, Venkatachalam TK, Uckun F. Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-]2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus. Bioorg Med Chem Lett 1999; 9: 1593-1598.
73. Mao C, Sudbeck EA,Venkatachalam, TK, Uckun F. Structure-based drug design of non-nucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase. Biochem Pharmacol 2000; 60: 1251-1265.
74. Vig R, Mao C, Venkatachalam TK, Tuel-Ahlgren L, Sudbeck EA, Uckun FM. Rational design and synthesis of phenethyl-5-bromopyridyl thiourea derivatives as potent non-nucleoside inhibitors of HIV reverse transcriptase. Bioorg Med Chem 1998; 6; 1789-1797.
75. Hannongbua S, Nivesanond K, Lawtrakul L, Pungop P, Wolschann P. 3D-Quantitative structure-activity relationships of HEPT derivatives as HIV-1 reverse transcriptase inhibitors, based on ab initio calculations. J Chem In. Comput Sci 2001; 41: 848-855.
76. Heeres J, de Jonge MR, Koymans LMH, Daeyaert FFD, Vinkers M, Van Aken KJA, Arnold E, Das K, Kilonda A, Hoornaert GJ, Compernolle F, Cegla M, Azzam RA, Andries K, de Bethune M-P, Azijn H, Pauwels R, Lewi PJ, Janssen PAJ. Design, synthesis, and SAR of novel pyrazinone series with nonnucleoside HIV-1 reverse transcriptase inhibitory activity. J Med Chem 2005; 48; 1910-1918.
77. Rodriguez-Barrios F, Gago, F. Chemometrical identification of mutations in HIV-1 reverse transcriptase conferring resistance or enhanced sensitivity to arylsulfonylbenzonitriles. J Amer Chem Soc 2004; 126: 2718-2719.
78. Jorgensen WL. Biochemical and Organic Model Builder (BOMB), Version 2.3, 2003; New Haven, CT, Yale University Press.
79. Jorgensen WL, (unpublished data).
80. Rodriguez-Barrios F, Gago F. Understanding the basis of resistance in the irksome Lys103Asn HIV-1 reverse transcriptase mutant through targeted molecular dynamics simulations. J Amer Chem Soc 2004; 126: 15386-15387.
81. Das K, Clark AD, Jr, Lewi PD, Heeres J, de Jonge MR, Koymans LMH, Vinkers HM, Daeyaert F, Ludovici DW, Kukla MJ, De Corte B, Kavash RW, Ho CY, Ye H, Lichtenstein MA, Andries K, Pauwels R, de Bethune M-P, Boyer P, Clark P, Hughes SH, Janssen PAJ, Arnold E. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (Etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004; 47: 2550-2560.
82. Udier BM, Tirado-Rives J, Jorgensen WL. Structural and Energetic Analyses of the Effects of the K103N Mutation of HIV-1 Reverse Transcriptase on Evafirenz analogues. J Med Chem 2004; 47: 2389-2392.
83. Ragno R, Mai A, Sbardella G, Artico M, Massa S, Musiu C, Mura M, Marturana F, Cadeddu A, La Colla P. Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2-,6- difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H0-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant. J Med Chem 2003; 47: 928-934.
84. Goodsell DS, Morris GM, Olson J. Automated docking of flexible ligands: Applications of AutoDock. J Mo Recognit 1996; 9: 1-5.
85. Ragno R, Frasca S, Manetti F, Brizzi A, Massa S. HIV-Reverse transcriptase inhibition: Inclusion of ligand-induced fit by cross-docking studies. J Med Chem 2005; 48: 200-212.
86. Radno R, Artico M, De Martino G, La Regina G, Coluccia A, Di Pasquali A, Silvestri R. Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives. J Med Chem 2005; 48: 213-223.
87. Chong Y, Borroto-Esoda K, Furman PA, Schinazi RF, Chu K. Molecular mechanism of DAPD/DXG against zidovudine- and lamivudine-drug resistant mutants: A molecular modeling approach. Antiviral Chem Chemother 2002; 13: 115-128.
88. White KL, Chen JM, Margot NA, Wrin T, Petropoulos CJ, Naeger LK, Swaminathan S, Miller MD. Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple typmidine analog-associated mutations. Antimicrob Agents Chemother 2004; 48: 992-1003.
89. Perryman AL, McCammon JA. AutoDocking dinucleotides to the HIV-1 integrase core domain: Exploring possible binding sites for viral and genomic DNA. J Med Chem 2002; 45: 5624-5627.
90. Menendez-Arias L, Este JA. HIV resistance to viral entry inhibitors. Curr Pharmaceut Des 2004; 10: 1845-1860.
91. Kilby JM, Hopkins S, Venetta TM, Dimassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews T, Johnson MR, Nowak MA, Shaw GM, Saag MS. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of Gp41-mediated virus entry. Nat Med 1998; 4: 1302-1307.
92. Jorgensen WL. The many roles of computation in drug discovery. Science 2004; 303: 1813-1818.
93. Hou T, Xu X. Recent development and application of virtual screening in drug discovery: an overview. Curr Pharm Des 2004; 10(9): 1011-33.
94. Mekenyan OG, Dimitrov SD, Pavlov TS, Veith GD. A systematic approach to simulating metabolism in computational toxicology. I. The TIMES heuristic modelling framework. Curr Pharm Des 2004; 10(11): 1273-93.
95. Reddy MR, Erion MD. Computer-aided drug design strategies used in the discovery of fructose 1,6-bisphosphatase inhibitors. Curr Pharm Des 2005; 11(3): 283-94.